Dutalfa Combipack
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Dutalfa Combipack is a combination of alfuzosin and dutasteride. Its labelling describes it for the treatment of an enlarged prostate gland (benign prostatic hyperplasia) in men, relieving symptoms such as difficulty urinating and needing to pass urine more frequently. Alfuzosin is described as relaxing the muscles around the prostate gland and bladder exit, while dutasteride decreases the hormone responsible for prostate growth and shrinks the gland, allowing easier urine flow. It does not prevent prostate cancer and can take up to four weeks to show visible improvement.
Product Information
The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of an enlarged prostate gland (benign prostatic hyperplasia) in men
- Described as relieving symptoms such as difficulty urinating and increased urinary frequency, improving flow and avoiding complete blockage
- Described as reducing prostate size and relaxing the muscles in the bladder and prostate; it does not prevent prostate cancer
Described Dosage & Administration
- Swallowed whole immediately after the same meal each day; the tablet should not be chewed, broken, or crushed
- Any specific guidance from the doctor should be followed diligently
- It can take up to four weeks for visible improvement; it should not be stopped even if the patient feels well
Described Side Effects
Commonly described side effects include:
- Impotence
- Decreased libido
- Ejaculation disorder
- Headache
- Nausea
- Abdominal pain
- Upper respiratory tract infection
- Breast enlargement and breast tenderness in males
- Dizziness
These are described as commonly temporary. The doctor should be informed if they persist.
Precautions
- Never prescribed for women and children, who must not take it
- The doctor should be informed beforehand of kidney or liver issues or low blood pressure
- Effective contraceptives should be used, and any blood tests cooperated with
- A complete medical history and list of current medications should be shared with the doctor
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it combines alfuzosin and dutasteride and is used for the treatment of an enlarged prostate gland (benign prostatic hyperplasia) in men. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as swallowed whole immediately after the same meal each day, without chewing, breaking, or crushing, and not stopped even if the patient feels well.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.